Orthogen

What Orthogen does

Orthogen İlaç San. Ltd. Şti is a privately held Turkish pharmaceutical company established in 2017 and headquartered in Çankaya, Ankara. The company manufactures and markets a focused portfolio of five branded pharmaceutical products spanning therapeutic categories including gynecology, urology, pediatrics, infertility treatment, digestive health, children's vitamins, pregnancy nutrition, and weight management. Its marketed SKUs are Femifol 50 Tablet (folic acid supplement), Nagflor Forte and Cerviron (vaginal ovules), Metilgen-B12 (methylcobalamin oral spray), and Marial Oral Gel (oral gel supplement). Product technology is centered on proprietary formulations for vaginal ovules, oral gels, and spray delivery systems, with active pharmaceutical ingredients and botanicals sourced from a network of international suppliers including Indena (Italy), Carnipure/Lonza, Pizeta, Sinerga, Lipofer, Fibruline, LifeInU, Livespo Global, İralab, and Hexanova. The portfolio is positioned as standalone pharmaceutical products rather than a unified platform architecture.

Orthogen operates a sales-led go-to-market model targeting healthcare professionals — primarily gynecologists, urologists, and pediatricians — who prescribe or recommend products through Turkey's pharmacy distribution network. The company has no disclosed pricing and no reported revenue; it is independently owned with no external investor, private equity, or venture capital signals in the source material, and operates exclusively within Turkey with no disclosed exports. Marketing and customer engagement are conducted through the company website (which features healthcare-worker verification gates and downloadable product summaries), WhatsApp Business, LinkedIn, and Instagram. The firm employs 51–100 people and carries a copyright notice spanning 2017–2026, consistent with continuous operations since founding. No M&A, funding rounds, regulatory actions, or leadership changes were disclosed in the available data.

Name

Orthogen

Legal name

Orthogen İlaç San. Ltd. Şti

Website

https://orthogen.com.tr

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Orthogen İlaç San. Ltd. Şti is a privately held Turkish pharmaceutical company that manufactures and markets branded prescription and OTC products in gynecology, urology, pediatrics, infertility, and digestive health, distributing through Turkish pharmacies via healthcare professional prescriptions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAJ

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Women's health products
• Therapeutic supplements
• Medical product distribution

Headquarters

HQ city

Çankaya

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: Orthogen generates revenue through the sale of pharmaceutical products including Femifol 50 Tablet (folic acid supplement), Nagflor Forte vaginal ovules, Cerviron vaginal ovules, Metilgen-B12 oral spray, and Marial Oral Gel. Products are distributed through pharmacies and prescribed by healthcare professionals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Orthogen is a Turkish pharmaceutical manufacturer founded in 2017 that produces a portfolio of prescription and therapeutic products including tablets, vaginal ovules, oral gels, and solutions. The company focuses on therapeutic areas such as gynecology, urology, pediatrics, infertility, digestive health, children's vitamins, pregnancy nutritional support, and weight management, distributing its products through pharmacies nationwide via a sales-led motion targeting healthcare professionals.

Product overview

Orthogen İlaç San. Ltd. Şti is a Turkish pharmaceutical company that manufactures and markets a portfolio of pharmaceutical products across multiple therapeutic categories. The company offers five distinct branded pharmaceutical products: Femifol 50 Tablet (folic acid supplement), Nagflor Forte 6 Vajinal Ovül (vaginal suppository), Metilgen-B12 10 Ml (methylcobalamin supplement), Cerviron 10 Vajinal Ovül (vaginal suppository), and Marial Oral Gel (oral gel supplement). These products address therapeutic areas including gynecology, urology, pediatrics, infertility, digestive health, children's vitamins, pregnancy nutritional support, and weight management. The portfolio consists of standalone pharmaceutical products rather than a unified platform architecture.

Differentiator

Problem solved

Functional benefit

Products and services

• Femifol 50 Tablet Tablet formulation listed within Orthogen's pharmaceutical product portfolio, distributed through pharmacies and presented on the company website with health worker verification gating.
• Nagflor Forte 6 Vajinal Ovül (Nagflor Forte 6 Vaginal Ovule) Vaginal ovule (suppository) formulation in a 6-unit pack within Orthogen's gynecology/women's health portfolio, distributed through pharmacies across Turkey.
• Metilgen-B12 10 Ml 10 ml vitamin B12 methylcobalamin solution within Orthogen's therapeutic supplement portfolio, distributed through pharmacies and gated by health worker verification on the company website.
• Cerviron 10 Vajinal Ovül (Cerviron 10 Vaginal Ovule) Vaginal ovule formulation in a 10-unit pack within Orthogen's gynecology/therapeutic portfolio, distributed through Turkish pharmacies for cervical/gynecological therapeutic use.
• Marial Oral Gel Oral gel formulation within Orthogen's pharmaceutical product portfolio, distributed through pharmacies and presented on the company website with health worker verification gating.

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights2 records

Broad incumbents

• Abdi İbrahim: Largest Turkish pharmaceutical manufacturer with a broad branded and generic portfolio across multiple therapeutic areas including women's health; directly comparable because both are domestic Turkish pharma companies competing in gynaecology and OTC categories.
• Sanofi Turkey: Multinational pharmaceutical incumbent with established Turkish operations spanning women's health, vitamins and OTC categories; comparable as a major competitor in Orthogen's pharmacy-distributed categories.
• Ferring Pharmaceuticals: Global pharmaceutical company specialising in reproductive health, women's health and gastroenterology; comparable as a women's health-focused player with overlapping therapeutic categories (infertility, gynaecology, digestive health).
• Organon: Global women's health-focused pharmaceutical company with franchises in fertility, contraception, and reproductive health; comparable therapeutic focus and physician-targeted sales motion.
• Eczacıbaşı İlaç: Major Turkish pharmaceutical and consumer health company with branded portfolios in women's health, vitamins and digestive categories; comparable as a domestic Turkish pharma peer with overlapping therapeutic categories.
• Bayer Turkey (Consumer Health): Multinational incumbent with strong women's health, prenatal vitamins and digestive health portfolios distributed via Turkish pharmacies; overlapping therapy lines and channel approach.

Emerging players

• Theramex: Specialty pharmaceutical company focused on women's health (contraception, fertility, menopause); comparable niche focus on women's reproductive health categories Orthogen addresses.
• Exeltis Turkey: Women's health specialty pharma company with prenatal supplements, fertility and gynaecology lines distributed in emerging markets including Turkey; comparable as a women's health-focused mid-sized player.

Direct peers

• Nobel İlaç: Turkish pharmaceutical manufacturer selling branded generics and innovative products across therapeutic categories including gynaecology and urology; directly comparable in business model, distribution channel and product mix.
• Berko İlaç: Turkish pharmaceutical company focused on women's health, paediatric vitamins and dermatology; highly comparable niche focus and pharmacy-led distribution model targeting gynaecologists and paediatricians.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orthogen-ilac
• Instagraminstagram.com/orthogen
• Facebookfacebook.com/eda.unal.988

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orthogen